WuXi Biologics (Cayman) Inc.

DB:1FW2 Stock Report

Market Cap: €8.9b

WuXi Biologics (Cayman) Past Earnings Performance

Past criteria checks 2/6

WuXi Biologics (Cayman) has been growing earnings at an average annual rate of 23.7%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 32.7% per year. WuXi Biologics (Cayman)'s return on equity is 6.7%, and it has net margins of 15.4%.

Key information

23.7%

Earnings growth rate

22.3%

EPS growth rate

Life Sciences Industry Growth26.8%
Revenue growth rate32.7%
Return on equity6.7%
Net Margin15.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How WuXi Biologics (Cayman) makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:1FW2 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2417,1162,6322,356788
31 Mar 2417,0753,0162,221787
31 Dec 2317,0343,4002,086786
30 Sep 2316,7943,7762,021769
30 Jun 2316,5544,1521,956753
31 Mar 2315,9114,2861,824718
31 Dec 2215,2694,4201,693683
30 Sep 2214,1794,2511,472670
30 Jun 2213,0904,0811,251657
31 Mar 2211,6903,7351,192579
31 Dec 2110,2903,3881,133502
30 Sep 219,1833,0921,043398
30 Jun 218,0752,795952295
31 Mar 216,8442,242837299
31 Dec 205,6121,689722304
30 Sep 204,9671,494648289
30 Jun 204,3211,300574275
31 Mar 204,1521,157512267
31 Dec 193,9841,014451260
30 Sep 193,535922427241
30 Jun 193,087831404222
31 Mar 192,811731365196
31 Dec 182,534631326169
30 Sep 182,277520270132
30 Jun 182,01941021494
31 Mar 181,81933119584
31 Dec 171,61925317574
30 Sep 171,42917715566
30 Jun 171,23314912860
31 Mar 171,11114511956
31 Dec 1698914111053
30 Sep 1688917110161
31 Dec 15557458640
31 Dec 14332424835

Quality Earnings: 1FW2 has high quality earnings.

Growing Profit Margin: 1FW2's current net profit margins (15.4%) are lower than last year (25.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 1FW2's earnings have grown significantly by 23.7% per year over the past 5 years.

Accelerating Growth: 1FW2's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 1FW2 had negative earnings growth (-36.6%) over the past year, making it difficult to compare to the Life Sciences industry average (-1.4%).

Return on Equity

High ROE: 1FW2's Return on Equity (6.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 13:50
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

WuXi Biologics (Cayman) Inc. is covered by 54 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Linda LuBOCI Research Ltd.
Wai Chak YuenBOCI Research Ltd.
Bo LiBofA Global Research